The Califf Factor: Commissioner Nominee's Role In IMPROVE-IT Gets Notice
Executive Summary
TIMI Study Group's Eugene Braunwald says Robert Califf, his co-chair on the IMPROVE-IT steering committee, 'worked very hard for nine-and-a-half years' on trial before leaving Duke to join FDA.
You may also be interested in...
IMPROVE-IT Study: Negative Panel Review Leaves FDA With Tough Choice
Approval of cardiovascular risk reduction claims for Merck's Zetia and Vytorin would fly in the face of advisory committee's recommendations, but rejection would mean the first outcomes study to show CV benefit for a non-statin, LDL-C-lowering agent did not provide substantial evidence.
Califf Nomination May Show Confidence In His Bipartisan Appeal
After seven months as deputy commissioner for medical products and tobacco, Robert Califf tapped to be FDA Commissioner.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.